ID30117A - Antagonis 5ht1 untuk terapi anti depresan - Google Patents

Antagonis 5ht1 untuk terapi anti depresan

Info

Publication number
ID30117A
ID30117A IDW00200101401A ID20011401A ID30117A ID 30117 A ID30117 A ID 30117A ID W00200101401 A IDW00200101401 A ID W00200101401A ID 20011401 A ID20011401 A ID 20011401A ID 30117 A ID30117 A ID 30117A
Authority
ID
Indonesia
Prior art keywords
antagonists
depression therapy
anti depression
therapy
depression
Prior art date
Application number
IDW00200101401A
Other languages
English (en)
Indonesian (id)
Inventor
Gene Michael Braight
Kishor Amratlal Desai
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID30117A publication Critical patent/ID30117A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDW00200101401A 1998-12-28 1999-11-03 Antagonis 5ht1 untuk terapi anti depresan ID30117A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11395798P 1998-12-28 1998-12-28

Publications (1)

Publication Number Publication Date
ID30117A true ID30117A (id) 2001-11-08

Family

ID=22352526

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101401A ID30117A (id) 1998-12-28 1999-11-03 Antagonis 5ht1 untuk terapi anti depresan

Country Status (43)

Country Link
US (1) US6525196B1 (fr)
EP (1) EP1140931B1 (fr)
JP (1) JP2002533463A (fr)
KR (1) KR100417506B1 (fr)
CN (1) CN1332740A (fr)
AP (1) AP2001002188A0 (fr)
AR (1) AR024840A1 (fr)
AT (1) ATE260278T1 (fr)
AU (1) AU761711B2 (fr)
BG (1) BG105710A (fr)
BR (1) BR9916807A (fr)
CA (1) CA2356985C (fr)
CO (1) CO5150179A1 (fr)
CR (1) CR6398A (fr)
CZ (1) CZ291163B6 (fr)
DE (1) DE69915113T2 (fr)
DK (1) DK1140931T3 (fr)
DZ (1) DZ2933A1 (fr)
EA (1) EA003099B1 (fr)
EE (1) EE04439B1 (fr)
ES (1) ES2214892T3 (fr)
GE (1) GEP20043227B (fr)
GT (1) GT199900224A (fr)
HR (1) HRP20010488A2 (fr)
HU (1) HUP0104852A3 (fr)
ID (1) ID30117A (fr)
IL (1) IL143385A0 (fr)
IS (1) IS5951A (fr)
MA (1) MA26706A1 (fr)
NO (1) NO20013215L (fr)
NZ (1) NZ511964A (fr)
OA (1) OA11742A (fr)
PA (1) PA8486701A1 (fr)
PE (1) PE20001234A1 (fr)
PT (1) PT1140931E (fr)
SK (1) SK9002001A3 (fr)
TN (1) TNSN99218A1 (fr)
TR (1) TR200101979T2 (fr)
TW (1) TW523514B (fr)
UA (1) UA62015C2 (fr)
WO (1) WO2000039128A1 (fr)
YU (1) YU44301A (fr)
ZA (1) ZA200105041B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065970A2 (fr) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Traitement de la fibromyalgie et du syndrome de fatigue associe au moyen d'antagonistes ou d'agonistes partiels de recepteurs 5ht1a
GB0203778D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
KR100767854B1 (ko) * 2003-03-12 2007-10-17 화이자 프로덕츠 인크. 피리딜옥시메틸 및 벤즈이속사졸 아자비시클릭 유도체
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
JP2007519705A (ja) * 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
WO2006027692A2 (fr) * 2004-09-10 2006-03-16 Pfizer Products Inc. Methodes destinees a traiter des troubles cognitifs au moyen de derives azabicycliques de pyridyloxymethyle et de benzisoxazole
WO2006027691A2 (fr) * 2004-09-10 2006-03-16 Pfizer Products Inc. Methodes de traitement des troubles de l'humeur au moyen de derives azabicycliques de pyridyloxymethyle et de benzisoxazole
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
WO2008019431A1 (fr) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Procédé et compositions pour réguler simultanément la mémoire et l'humeur
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2020183011A1 (fr) 2019-03-14 2020-09-17 Institut Curie Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer
US20230057844A1 (en) * 2019-12-20 2023-02-23 The Jackson Laboratory Molecular targets for addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
US5756496A (en) * 1994-05-28 1998-05-26 Smithkline Beecham P.L.C. Amide derivatives having 5HT1D-antagonist activity
KR20010006487A (ko) * 1997-04-18 2001-01-26 피터 기딩스 조합된 5ｈｔ1ａ, 5ｈｔ1ｂ 및 5ｈｔ1ｄ 수용체 길항 활성을 갖는 인돌 유도체
IT1293807B1 (it) * 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1

Also Published As

Publication number Publication date
EA003099B1 (ru) 2002-12-26
JP2002533463A (ja) 2002-10-08
HUP0104852A2 (hu) 2002-05-29
EE200100346A (et) 2002-12-16
UA62015C2 (en) 2003-12-15
IL143385A0 (en) 2002-04-21
TR200101979T2 (tr) 2001-12-21
PE20001234A1 (es) 2000-11-07
CA2356985A1 (fr) 2000-07-06
WO2000039128A1 (fr) 2000-07-06
DZ2933A1 (fr) 2004-03-15
CZ20012386A3 (cs) 2002-02-13
TW523514B (en) 2003-03-11
CZ291163B6 (cs) 2003-01-15
OA11742A (en) 2005-05-13
US6525196B1 (en) 2003-02-25
DE69915113D1 (de) 2004-04-01
CA2356985C (fr) 2006-08-08
AP2001002188A0 (en) 2001-06-30
NO20013215L (no) 2001-08-27
DE69915113T2 (de) 2004-08-26
SK9002001A3 (en) 2002-04-04
EP1140931B1 (fr) 2004-02-25
YU44301A (sh) 2004-07-15
PA8486701A1 (es) 2000-09-29
NO20013215D0 (no) 2001-06-27
GT199900224A (es) 2001-06-15
PT1140931E (pt) 2004-05-31
CN1332740A (zh) 2002-01-23
AU761711B2 (en) 2003-06-05
DK1140931T3 (da) 2004-04-19
ZA200105041B (en) 2002-06-20
NZ511964A (en) 2003-08-29
ATE260278T1 (de) 2004-03-15
ES2214892T3 (es) 2004-09-16
BG105710A (en) 2002-02-28
GEP20043227B (en) 2004-04-26
EE04439B1 (et) 2005-02-15
IS5951A (is) 2001-05-22
KR20010092455A (ko) 2001-10-25
HRP20010488A2 (en) 2002-08-31
EP1140931A1 (fr) 2001-10-10
TNSN99218A1 (fr) 2005-11-10
KR100417506B1 (ko) 2004-02-05
HUP0104852A3 (en) 2002-12-28
EA200100517A1 (ru) 2001-12-24
CO5150179A1 (es) 2002-04-29
AU6361499A (en) 2000-07-31
AR024840A1 (es) 2002-10-30
BR9916807A (pt) 2001-10-23
CR6398A (es) 2004-03-24
MA26706A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
ID18003A (id) Antagonis muskarinik
DE69834019D1 (de) Dose
ID27841A (id) Turunan-turunan biaril terapeutik
NO20004688L (no) Terapi ved østrogenassosierte lidelser
EE9900540A (et) Omeprasooli ravimvorm
NO20010556L (no) Fremgangsmate for oftalmisk administrering
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
ID19623A (id) Antagonis reseptor vitronektin
DE60000003T2 (de) Paroxetinmethansulfonat
EE200000171A (et) Uued NPY antagonistid
ID30117A (id) Antagonis 5ht1 untuk terapi anti depresan
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
ID26223A (id) Antagonis reseptor vitronektin
ID29128A (id) Gen untuk biosintesis epotilon
ID26665A (id) Antagonis vla-4
ID29914A (id) Senyawa benzensulfonamida heterosiklik sebagai antagonis bradikinin
ID26086A (id) Ligan-ligan reseptor 5ht1 azabisiklik
ID22838A (id) Oksazolidina sebagai antagonis 5-ht2a
ID27845A (id) Turunan tetrahidrokuilina sebagai antagonis glisilina
ID28811A (id) Antagonis reseptor vitronektin
NO990717D0 (no) Monitor-st°ttemekanisme
NO20012226L (no) Terapeutiske midler for medikamentavhengighet
ID27943A (id) Pelat untuk peralatan pengkawatan
ID22978A (id) Antagonis reseptor endotelin
SI1140931T1 (en) 5ht1 antagonists for antidepressant therapy